[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-368375-105":59,"doc-detail-368375-en":131},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":124,"head_meta":126,"extra_data":128,"updated_unix":130},105,"en","plain-language-summary-of-the-results-from-the-magnitude-study-assessing-how-effective-and-how-safe-niraparib-and-abiraterone-acetate-with-prednisone-are-in-patients-with-metastatic-castration-resistant-prostate-cancer","Plain Language Summary of the Results from the MAGNITUDE Study - Assessing How Effective and How Safe Niraparib and Abiraterone Acetate With Prednisone Are in Patients With Metastatic Castration-Resistant Prostate Cancer","","Plain language summary of the MAGNITUDE clinical study examining the effectiveness and safety of niraparib plus abiraterone acetate with prednisone as a first treatment for adults with metastatic castration-resistant prostate cancer. The study focused on whether outcomes differ in patients whose tumors carry homologous recombination repair (HRR) gene alterations, particularly BRCA1/2. Key results include longer time before worsening for HRR+ patients versus HRR-negative patients and higher side-effect rates that were generally managed through dose pauses or reductions.",{"@graph":69,"@context":123},[70,84,106],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":35,"@type":76,"position":81},"https://docshare.wps.com/document/healthcare/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/plain-language-summary-of-the-results-from-the-magnitude-study-assessing-how-effective-and-how-safe-niraparib-and-abiraterone-acetate-with-prednisone-are-in-patients-with-metastatic-castration-resistant-prostate-cancer/368375/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/plain-language-summary-of-the-results-from-the-magnitude-study-assessing-how-effective-and-how-safe-niraparib-and-abiraterone-acetate-with-prednisone-are-in-patients-with-metastatic-castration-resistant-prostate-cancer/368375.png","ImageObject",300,407,{"name":92,"@type":93},"Ophelia","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-11-03","2026-09-23",true,{"@type":102,"interactionType":103,"userInteractionCount":105},"InteractionCounter",{"@type":104},"ViewAction",12,{"@type":107,"mainEntity":108},"FAQPage",[109,115,119],{"name":110,"@type":111,"acceptedAnswer":112},"What treatment combination did the MAGNITUDE summary evaluate for metastatic castration-resistant prostate cancer?","Question",{"text":113,"@type":114},"The summary evaluates niraparib combined with abiraterone acetate plus prednisone as a first treatment, compared with placebo plus abiraterone acetate with prednisone.","Answer",{"name":116,"@type":111,"acceptedAnswer":117},"How did HRR gene changes relate to when the cancer worsened?",{"text":118,"@type":114},"Patients with BRCA1/2 changes had a longer time before their cancer worsened (16.6 months) compared with those without such changes (10.9 months).",{"name":120,"@type":111,"acceptedAnswer":121},"What safety results were reported for patients taking niraparib plus abiraterone acetate with prednisone?",{"text":122,"@type":114},"More patients experienced side effects in the niraparib combination group (99.1%) versus placebo (94.3%), and the summary notes these side effects were generally manageable by pausing treatment or lowering the dose.","https://schema.org",{"og:url":83,"og:type":125,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":127,"canonical":83},"index,follow",{"doc_id":129,"site_id":62},368375,1790320002,{"code":4,"msg":5,"data":132},{"doc_id":129,"user_id":133,"nickname":92,"user_avatar":134,"doc_module":4,"category_id":34,"category_name":35,"doc_title":65,"doc_description":67,"doc_content":135,"file_id":136,"file_url":137,"file_type":138,"file_size":139,"view_count":105,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":56,"language":140,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":141,"faqs":142,"seo_title":143,"seo_description":67,"update_tm":144,"read_time":145},7971461741311,"https://ap-avatar.wpscdn.com/avatar/74000253aff267980c6?x-image-process=image/resize,m_fixed,w_180,h_180&k=1779345379180704826","Plain Language Summary of Publication  \nA plain language summary of the results from the MAGNITUDE study assessing how effective and how safe niraparib and abiraterone acetate with prednisone is in patients with metastatic castration-resistant prostate cancer  \nKim N. Chia, Dana Rathkopfb, Matthew R. Smithc, Eleni Efstathioud, Gerhardt Attarde, David Olmosf, Ji Youl Leeg, Eric J. Smallh,  \nAndrea J. Pereira de Santana Gomesi, Guilhem Roubaudj, Marniza Saadk, Bogdan Zurawskil, Valerii Sakalom, Gary E. Masonn, Peter Franciso, George Wangn, Daphne Wup, Brooke Diorioq, Angela Lopez-Gitlitzp & Shahneen Sandhur  \nAuthor affiliations can be found at the end of this article  \nFirst draft submitted: 8 February 2024; Accepted for publication: 18 February 2025  \nWhere can I find the original article on which this summary is based?  \nResults from the first analysis of the MAGNITUDE study were published in the Journal of Clinical Oncology in March 2023,‘Nirapariband Abiraterone Acetate for Metastatic Castration-Resistant Prostate Cancer’. This can be read for free at: [https://ascopubs.org/](https://ascopubs.org/)[ ](https://ascopubs.org/)[doi/10.1200/JCO.22.01649](doi/10.1200/JCO.22.01649.)[.](doi/10.1200/JCO.22.01649.)  \nResults from the second analysis, performed 8 months after the first analysis, were published in Annals of Oncology in September 2023,‘Niraparib plus abiraterone acetate with prednisone in patients with metastatic castration-resistant prostate cancer and homologous recombination repair gene alterations: second interim analysis of the randomized phase III MAGNITUDE trial’. This can be read for free  \nat: [https://www.annalsofoncology.org/article/S0923-7534(23)00757-3/fulltext](https://www.annalsofoncology.org/article/S0923-7534(23)00757-3/fulltext.)[.](https://www.annalsofoncology.org/article/S0923-7534(23)00757-3/fulltext.)  \nSummary  \nWhat is this summary about?  \nThis is a summary of the MAGNITUDE clinical study that was published in the Journal of Clinical Oncology (March 2023) and in Annals of Oncology (September 2023) .  \nResearchers looked at the combination of niraparib and abiraterone acetate with prednisone as a first treatment for adult patients with metastatic castration-resistant prostate cancer.  \nResearchers wanted to know how effective and safe niraparib + abiraterone acetate with prednisone is in patients whose cancers had certain gene changes.  \n• Researchers focused on genes related to homologous recombination repair (HRR), a normal process that repairs damaged DNA.  \nHow to say (download PDF and double click sound icon to play sound)...  \n• Niraparib: nih-rap-uh-rib  \n• Abiraterone acetate: A-bih-ra-teh-ronea-seh-tayt  \n• Prednisone: pred-nih-zown  \n• Metastatic: meh-tuh-sta-tik  \n• Castration: ka-stray-shuhn  \n• Prostate: proh-stayt  \n• Placebo: pluh-see-bow  \n• Testosterone: teh-sto-stuh-rown  \n• Androgen: an-druh-jen  \n• The best understood HRR genes are BRCA1 and BRCA2 (which code for BReast CAncer susceptibility 1 and 2 proteins) that are changed in 3–13% of patients with metastatic castration-resistant prostate cancer. We refer to these genes as BRCA1/2 .  \n• Compared with cancers that lack these changes, cancers with changes in HRR genes (HRR+) may not respond as well to treatments that are normally used for metastatic castration-resistant prostate cancer, such as abiraterone acetate with prednisone.  \nWhat were the main conclusions reported by the researchers?  \nPatients who had BRCA1/2 changes had a longer time (16.6 months) before their cancer worsened compared with those who did not (10.9 months) .  \n10. 1080/14796694 .2025. 2470106 © 2025 The Author(s). Published by Informa UK Limited, trading as Taylor & Francis Group  \nThis is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivatives License ([http://crea](http://crea)[tivecommons.org/licenses/by-nc-nd/4.0/](tivecommons.org/licenses/by-nc-nd/4.0/)), which permits non-commercial re-u","cbCaigsVRsaJOlo4","https://ap.wps.com/l/cbCaigsVRsaJOlo4","pdf",4309911,"English","# Summary\n## What is this summary about?\n## How is the study structured?\n## What were the main conclusions?\n## Side effects and management\n## What are the key takeaways?","[{\"question\":\"What treatment combination did the MAGNITUDE summary evaluate for metastatic castration-resistant prostate cancer?\",\"answer\":\"The summary evaluates niraparib combined with abiraterone acetate plus prednisone as a first treatment, compared with placebo plus abiraterone acetate with prednisone.\"},{\"question\":\"How did HRR gene changes relate to when the cancer worsened?\",\"answer\":\"Patients with BRCA1/2 changes had a longer time before their cancer worsened (16.6 months) compared with those without such changes (10.9 months).\"},{\"question\":\"What safety results were reported for patients taking niraparib plus abiraterone acetate with prednisone?\",\"answer\":\"More patients experienced side effects in the niraparib combination group (99.1%) versus placebo (94.3%), and the summary notes these side effects were generally manageable by pausing treatment or lowering the dose.\"}]","Plain Language Summary of the Results from the MAGNITUDE Study - Assessing How Effective and How Safe Niraparib and Abiraterone Acetate With Prednisone Are in Patients With Metastatic Castration-Resistant Prostate Cancer | PDF",1790176593,48]